A Phase 4 interventional study of Ticagrelor and Placebo in Myocardial Infarction and Segment Elevation Myocardial Infarction (STEMI), sponsored by AstraZeneca. Completed at 101 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-22.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing ticagrelor in Myocardial Infarction — 3 open to participants now, 3 under way, 1 of them phase 3. Ticagrelor · Myocardial Infarction.
Among the 36 studies testing ticagrelor in Myocardial Infarction, this one is the 8th largest by enrollment, is the only one that started in 2011, is one of 20 in phase 4, and was the 5th registered.
2,274 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.
Browse Myocardial Infarction studies →3 of the 36 studies testing ticagrelor in Myocardial Infarction are open now, in 7 countries. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Ireland, Latvia, Norway and 2 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Nova Scotia Health Authority · Sites in Canada
Ages 55+
By country, each count listing its studies:
Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,875 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 132 across the 36 interventional studies. Of the 26 that completed or were terminated, 12 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
20 studies in Myocardial Infarction by AstraZeneca: none open now, none under way, none of them phase 3. Of 20 finished, 10 (50%) have results posted.
Among the 20 studies in Myocardial Infarction by AstraZeneca, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2011, is one of 2 in phase 4, and was the 8th registered.
AstraZeneca’s Myocardial Infarction studies by the year they started, since 2000.
1 of the studies testing ticagrelor in Myocardial Infarction that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing ticagrelor in Myocardial Infarction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 20 in Myocardial Infarction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to determine whether initiation of ticagrelor as early as in the ambulance setting leads to a rapid reperfusion of the infarct-related artery therefore facilitating the Percutaneous Coronary Intervention (PCI) and optimizing the outcome for the patient.
The study will assess the efficacy and safety of pre-hospital compared to in-hospital administration of ticagrelor in co-administration with aspirin, on restoring the blood flow in the occluded heart artery and improving the myocardial perfusion in patients suffering from myocardial infarction and planned to have a PCI. Patients can be randomised in either one of the 2 arms:
re-hospital ticagrelor arm: Patients will receive a loading dose of 180 mg ticagrelor for the pre-hospital administration and placebo for in-hospital administration.
or In-hospital ticagrelor arm: Patients will receive a placebo for pre-hospital administration and 180 mg ticagrelor loading dose for in-hospital administration.
Patients are initially managed by ambulance physician/personnel in pre hospital settings. They are then transferred into a Catheterization room to undergo a PCI.
After the administration of the loading dose of ticagrelor (double blind), patients will continue on ticagrelor 90 mg bid and be followed in study for 30 days post randomisation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
Drug: Ticagrelor
Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
Drug: Placebo
Oral Ticagrelor loading dose (180 mg) followed by matching placebo
Placebo followed by oral Ticagrelor loading dose (180 mg)
Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint)
(TIMI) flow grade classification is used to assess coronary blood flow in acute coronary syndromes. grade 0:no reperfusion, grade 1: penetration without perfusion, grade 2: Partial reperfusion, grade 3: complete perfusion.
Time frame: At initial angiography, pre PCI
ST-segment Elevation Resolution Pre PCI ≥70% (Co-primary Endpoint)
ST segment elevation resolution is the mean ST elevation pre-hospital minus the mean STelevation pre-PCI divided by the mean ST elevation pre-hospital. It is expressed as a percentage and split in 2 categories , complete (≥70%) versus incomplete (\<70%) resolution.
Time frame: Between baseline and PCI
1st Composite Clinical Endpoint
death/MI/stroke/urgent revascularization/stent thrombosis. Adjudicated events except death
Time frame: during the 30 days of treatment
2nd Composite Clinical Endpoint
Death/MI/urgent revascularization. Adjudicated events except death
Time frame: within 30 days of study
Definite Stent Thrombosis
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. It is an adjudicated endpoint
Time frame: during 30 days of treatment
TIMI Flow Grade 3 Post -PCI
TIMI) flow grade 3 is complete perfusion post-PCI.
Time frame: at coroangiography post-PCI
ST Segment Elevation Resolution Post-PCI >= 70%
ST segment elevation resolution post PCI \>=70% is defined as complete resolution
Time frame: Between baseline and ECG 60 mn post-PCI
Thrombotic Bail-out With GPIIb/IIIa Inhibitors at Initial PCI
Glycoprotein (GP) IIb/IIIa inhibitors are often used as a rescue or bailout therapy to manage complications arising during percutaneous coronary intervention.
Time frame: during PCI
Major Bleeds Within 48 Hours
non CABG related bleeds, (PLATO definition) include Life threatening and other major bleeds
Time frame: within 48 hours of first dose
Minor and Major Bleedings Within 48 Hours
non CABG related bleeds (PLATO definition)
Time frame: within 48 hours of first dose
Major Bleeds After 48 Hours
non CABG related bleeds (PLATO definition) include life threatening and other major bleedings
Time frame: after 48hours post-first dose
Minor and Major Bleeds After 48 Hours
non CABG related bleeds (PLATO definition)
Time frame: after 48 hours post first dose
Patients were randomized in pre-hospital settings at 102 Emergency Medical Services between September 2011 and October 2013. 1875 patients were recruited in the study, 1862 consented patients were randomized.
| Milestone | Pre-hospital Ticagrelor | In-hospital Ticagrelor |
|---|---|---|
| Started | 909 | 953 |
| Modified intent to treat population | 906 | 952 |
| Safety population | 908 | 950 |
| Completed | 844 | 897 |
| Not completed | 65 | 56 |
| Withdrew: Withdrawal by subject | 13 | 23 |
| Withdrew: Death | 30 | 19 |
| Withdrew: Protocol violation | 10 | 7 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Had other reason | 9 | 6 |
(TIMI) flow grade classification is used to assess coronary blood flow in acute coronary syndromes. grade 0:no reperfusion, grade 1: penetration without perfusion, grade 2: Partial reperfusion, grade 3: complete perfusion.
| patients | Pre-hospital Ticagrelor | In-hospital Ticagrelor |
|---|---|---|
| Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint) | 143 | 145 |
ST segment elevation resolution is the mean ST elevation pre-hospital minus the mean STelevation pre-PCI divided by the mean ST elevation pre-hospital. It is expressed as a percentage and split in 2 categories , complete (≥70%) versus incomplete (\<70%) resolution.
| patients | Pre-hospital Ticagrelor | In-hospital Ticagrelor |
|---|---|---|
| ST-segment Elevation Resolution Pre PCI ≥70% (Co-primary Endpoint) | 102 | 102 |
death/MI/stroke/urgent revascularization/stent thrombosis. Adjudicated events except death
| patients | Pre-hospital Ticagrelor | In-hospital Ticagrelor |
|---|---|---|
| 1st Composite Clinical Endpoint | 41 | 42 |
Death/MI/urgent revascularization. Adjudicated events except death
| patients | Pre-hospital Ticagrelor | In-hospital Ticagrelor |
|---|---|---|
| 2nd Composite Clinical Endpoint | 39 | 34 |
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. It is an adjudicated endpoint
| patients | Pre-hospital Ticagrelor | In-hospital Ticagrelor |
|---|---|---|
| Definite Stent Thrombosis | 2 | 11 |
TIMI) flow grade 3 is complete perfusion post-PCI.
| patients | Pre-hospital Ticagrelor | In-hospital Ticagrelor |
|---|---|---|
| TIMI Flow Grade 3 Post -PCI | 625 | 630 |
ST segment elevation resolution post PCI \>=70% is defined as complete resolution
| patients | Pre-hospital Ticagrelor | In-hospital Ticagrelor |
|---|---|---|
| ST Segment Elevation Resolution Post-PCI >= 70% | 410 | 390 |
Glycoprotein (GP) IIb/IIIa inhibitors are often used as a rescue or bailout therapy to manage complications arising during percutaneous coronary intervention.
| patients | Pre-hospital Ticagrelor | In-hospital Ticagrelor |
|---|---|---|
| Thrombotic Bail-out With GPIIb/IIIa Inhibitors at Initial PCI | 78 | 100 |
non CABG related bleeds, (PLATO definition) include Life threatening and other major bleeds
| patients | Pre-hospital Ticagrelor | In-hospital Ticagrelor |
|---|---|---|
| Major Bleeds Within 48 Hours | 16 | 15 |
non CABG related bleeds (PLATO definition)
| patients | Pre-hospital Ticagrelor | In-hospital Ticagrelor |
|---|---|---|
| Minor and Major Bleedings Within 48 Hours | 24 | 24 |
non CABG related bleeds (PLATO definition) include life threatening and other major bleedings
| patients | Pre-hospital Ticagrelor | In-hospital Ticagrelor |
|---|---|---|
| Major Bleeds After 48 Hours | 11 | 11 |
non CABG related bleeds (PLATO definition)
| patients | Pre-hospital Ticagrelor | In-hospital Ticagrelor |
|---|---|---|
| Minor and Major Bleeds After 48 Hours | 18 | 16 |
Collected over within 30 days of study. Non-serious events are listed at a 3.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ticagrelor In-Hosp | — | 143/950 (15.1%) | 529/950 (55.7%) |
| Ticagrelor Pre-Hosp | — | 140/908 (15.4%) | 469/908 (51.7%) |
| Event | Ticagrelor In-Hosp | Ticagrelor Pre-Hosp |
|---|---|---|
| VENTRICULAR FIBRILLATIONCardiac disorders | 30/950 | 23/908 |
| CARDIOGENIC SHOCKCardiac disorders | 16/950 | 17/908 |
| CARDIAC ARRESTCardiac disorders | 7/950 | 11/908 |
| CARDIAC FAILURECardiac disorders | 7/950 | 7/908 |
| VENTRICULAR TACHYCARDIACardiac disorders | 7/950 | 6/908 |
| NON-CARDIAC CHEST PAINGeneral disorders | 5/950 | 4/908 |
| ATRIAL FIBRILLATIONCardiac disorders | 2/950 | 4/908 |
| PULMONARY OEDEMARespiratory, thoracic and mediastinal disorders | 1/950 | 4/908 |
| INTRACARDIAC THROMBUSCardiac disorders | 4/950 | 2/908 |
| PERICARDIAL EFFUSIONCardiac disorders | 4/950 | 0/908 |
| Event | Ticagrelor In-Hosp | Ticagrelor Pre-Hosp |
|---|---|---|
| DyspnoeaGastrointestinal disorders | 86/950 | 62/908 |
| Ventricular tachycardiaCardiac disorders | 81/950 | 79/908 |
| Non cardiac chest painGeneral disorders | 52/950 | 42/908 |
| NauseaGastrointestinal disorders | 49/950 | 41/908 |
| HypotensionVascular disorders | 30/950 | 44/908 |
| VomitingGastrointestinal disorders | 40/950 | 34/908 |
| Atrial fibrillationCardiac disorders | 38/950 | 30/908 |
| Ventricular fibrillationCardiac disorders | 37/950 | 32/908 |
| Cardiac failureCardiac disorders | 33/950 | 30/908 |
| HeadacheNervous system disorders | 31/950 | 19/908 |
| Age, Continuous(Years) | Pre-hospital Ticagrelor | In-hospital Ticagrelor | Total |
|---|---|---|---|
| Years | 60.6 ± 12.38 | 61.0 ± 12.49 | 60.8 ± 12.43 |
| Sex: Female, Male(Participants) | Pre-hospital Ticagrelor | In-hospital Ticagrelor | Total |
|---|---|---|---|
| Female | 173 | 196 | 369 |
| Male | 736 | 757 | 1493 |
| Diabetes mellitus(patients) | Pre-hospital Ticagrelor | In-hospital Ticagrelor | Total |
|---|---|---|---|
| yes | 115 | 138 | 253 |
| no/unknown | 794 | 815 | 1609 |
| TIMI risk score(patients) | Pre-hospital Ticagrelor | In-hospital Ticagrelor | Total |
|---|---|---|---|
| 0-2 | 552 | 573 | 1125 |
| 3-6 | 337 | 365 | 702 |
| >6 | 20 | 15 | 35 |
| Killip class(patients) | Pre-hospital Ticagrelor | In-hospital Ticagrelor | Total |
|---|---|---|---|
| I | 819 | 862 | 1681 |
| II, III, IV | 51 | 43 | 94 |
| unknown | 39 | 48 | 87 |
| First medical contact(patients) | Pre-hospital Ticagrelor | In-hospital Ticagrelor | Total |
|---|---|---|---|
| in ambulance | 689 | 723 | 1412 |
| in emergency department | 220 | 230 | 450 |
| PCI(Patients) | Pre-hospital Ticagrelor | In-hospital Ticagrelor | Total |
|---|---|---|---|
| yes | 800 | 830 | 1630 |
| no | 109 | 123 | 232 |
| type of PCI(patients) | Pre-hospital Ticagrelor | In-hospital Ticagrelor | Total |
|---|---|---|---|
| with stent | 760 | 776 | 1536 |
| without stent | 40 | 54 | 94 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 101 sites across 13 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2011, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor